IP Library Granted Patent US 8,877,773
Granted Patent B2
US 8,877,773 · App. 13/503,609 · Granted Nov 4, 2014

Methods for treating chronic obstructive pulmonary disease

Inventors: Anantha Shekhar (Indianapolis, IN); Philip L. Johnson (Indianapolis, IN)
A61K31/438G01N2800/301G01N2800/52G01N2800/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,773
App. No.
13/503,609
Granted
Nov 4, 2014
Kind
B2
Abstract

Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed.

Claims (5)

1. A method of treating hypercapnia-induced anxiety associated with chronic obstructive pulmonary disease in an individual, the method comprising administering to the individual suffering from chronic obstructive pulmonary disease a composition comprising a therapeutically effective amount of an agent to down regulate the activity of an orexin, Orexin A, wherein the agent is an orexin receptor antagonist for orexin 1 receptors; wherein the effective amount treats hypercapnia-induced anxiety associated with chronic obstructive pulmonary disease in the individual wherein the effective amount treats hypercapnia-induced anxiety without altering the robust bradycardia response.

2. The method of claim 1 , wherein the orexin receptor antagonist is selected from SB334867, and SB408124.

3. The method of claim 1 , wherein the orexin receptor antagonist comprises about 30 mg/kg.

4. The method of claim 1 , wherein the orexin receptor antagonist is administered by a route selected from the group consisting of orally and parenterally.

5. The method of claim 1 , wherein the orexin receptor antagonist is administered by a route selected from the group consisting of intranasally, inhalable, intramuscularly, intraperitoneally; intravenously, intraventricularly, intraspinally, intrarectally, ipsalaterally and subcutaneously.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 21, 2012
From: INDIANA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028818/0801 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: SHEKHAR, ANANTHA; JOHNSON, PHILIP L.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 028434/0404 →
Continuity (3)
Provisional Application 61254689 · Oct 24, 2009
Provisional Application 61388965 · Oct 1, 2010
Related Publication 20120269810A1 · Oct 25, 2012